ESTEVE
History
| Year | Detail |
|---|---|
| 1929 | ESTEVE, a global pharmaceutical company headquartered in Barcelona, Spain, was founded by Dr. Antoni Esteve i Subirana. |
| 1931 | The company developed its first vitamin specialties, Esterocal and Esterosol. |
| 1954 | The company started to expand internationally by exporting antihemorrhagic 101 and etamsylate. |
| 1974 | The company joint ventured with PUIG and established ISDIN, which specializes in dermatology. |
| 2019 | ESTEVE acquired Riemser, a pharma company with affiliates in Germany, the UK, and France, from Ardian. The acquisition provided the company with a more significant pharmaceutical presence in Europe's main markets and a portfolio of proprietary specialty products for hospital use. |
| 2020 | ESTEVE and LEITAT partnered to create WeLab, a bio incubator, accelerator hub, and center of excellence for biomedicine and pharma in Spain. |
| 2022 | The company collaborated with MEDTRONIC to increase awareness of cancer pain as well as to optimize the timely use of intrathecal drug delivery (IDD) therapy for patients suffering from complex and refractory pain induced by cancer or cancer treatment. |
| 2024 | The company acquired HRA Pharma Rare Diseases, a business specializing in rare diseases, from Perrigo Company plc. to expand its portfolio in rare and severe diseases. It added three new medications to treat Cushing's syndrome and adrenocortical carcinoma: Metopirone, Lysodren, and Ketoconazole HRA. |
BCC Research Beacon 